Significant improvements in the outcome of children with acute lymphoblastic leukemia have derived from the application of risk-adapted therapy. Age of the patient, laboratory features at diagnosis, biologic characteristics of the blasts, and early response to therapy, as measured both by conventional morphology and using technologies to detect minimal residual disease, all have been shown to affect outcome in ALL. In spite of improved outcomes, many patients who fail are those with good risk characteristics. Moreover, some patients are treated more intensively than they need to be may suffer from unnecessary toxicity. We hypothesize that the stratification of acute lymphoblastic leukemia can be improved by investigating the importance of different prognostic factors within homogeneously defined and treated subgroups of patients with ALL. To do this requires study of large numbers of patients;thus, we will carry out these studies in association with the phase III clinical trials of the Children's Oncology Group. In previous studies we have shown that we can use centralized reference laboratories to perform genetic stratification of patients in real time, and use the results to assign patients to treatment protocols based on genetic risk factors. We have also shown that in >95% of patients we can successfully measure minimal residual disease (MRD) in a timely fashion, and in so doing provide important prognostic information. The studies proposed in this grant will extend previous findings to different groups of patients and different time points, with the hope of further refining the ability to assign patients to optimal therapy. We plan to identify the relative contribution of genetic lesions, early marrow response, minimal residual disease, and NCI risk group classification to the overall prognosis of specific subsets of children with acute leukemia;to determine if we can combine favorable biological and response prognostic factors to identify patients who can be cured with minimal therapy;and to use minimal residual disease testing to identify additional patients who might benefit from therapeutic intensification, possibly including marrow transplantation. These studies will give us a better understanding of how to use prognostic information in treating children with ALL, and bring us closer to our goal of curing the maximum number of children with ALL with the least toxic therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA086011-09
Application #
7667291
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Merritt, William D
Project Start
2000-04-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
9
Fiscal Year
2009
Total Cost
$561,044
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Borowitz, Michael J (2014) Mixed phenotype acute leukemia. Cytometry B Clin Cytom 86:152-3
Dunsmore, Kimberly P; Devidas, Meenakshi; Linda, Stephen B et al. (2012) Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 30:2753-9
Chen, I-Ming; Harvey, Richard C; Mullighan, Charles G et al. (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 119:3512-22
Bowman, W Paul; Larsen, Eric L; Devidas, Meenakshi et al. (2011) Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. Pediatr Blood Cancer 57:569-77
Maloney, Kelly W; Carroll, William L; Carroll, Andrew J et al. (2010) Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 116:1045-50
Yang, Jun J; Cheng, Cheng; Yang, Wenjian et al. (2009) Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403
Mullighan, Charles G; Su, Xiaoping; Zhang, Jinghui et al. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-80
Borowitz, Michael J; Devidas, Meenakshi; Hunger, Stephen P et al. (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111:5477-85
Borowitz, Michael J; Pullen, D Jeanette; Winick, Naomi et al. (2005) Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom 68:18-24
Borowitz, M J; Pullen, D J; Shuster, J J et al. (2003) Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 17:1566-72